IceCure Medical, developer of minimally invasive cryoablation technology, the ProSense System (marketed under the brand name IceSense3 in China), that destroys tumours by freezing as an alternative to surgical tumour removal, has announced the National Medical Products Administration (NMPA) of China approved the company’s IceSense3 disposable cryoprobes for commercial use, to be used in combination with the company’s IceSense3 console, which was previously approved by the NMPA.
With this latest approval, the company and its partners in China can address a significant market with its novel and proven technology to treat malignant and benign tissue of the breast, lung, bone, liver, and kidneys, as well as palliative interventions.
“With approximately 430,000 new breast cancer cases in 2022 alone, and a healthcare system readily adopting new technologies that produce improved outcomes, we see China as a prime market for our cryoablation system,” stated Eyal Shamir, IceCure’s chief executive officer. “Having received regulatory approval for commercial sales of both our console and cryoprobes, we expect to effectively monetise our distribution agreement in the Chinese market.”
